Pediatric choroidal neovascularization: Etiology and treatment outcomes with anti-vascular endothelial growth factors.
Eur J Ophthalmol
; 32(4): 2355-2367, 2022 Jul.
Article
in En
| MEDLINE
| ID: mdl-34615395
ABSTRACT
PURPOSE:
To describe the etiology and treatment outcomes of choroidal neovascularization (CNV) in a pediatric population with intravitreal anti-vascular endothelial growth factors (VEGF).METHODS:
Retrospective single center interventional case series. A total of 26 eyes of 23 consecutive pediatric patients with CNV of various etiologies were treated with intravitreal injection of anti-VEGF agents.RESULTS:
There were 15 males (65.2%) and eight females (34.8%), diagnosed with CNV during the study period. The mean age at presentation with CNV was 11.7 ± 3.3 years, (range 4-16 years) and the mean follow was 28.1 ± 18 months, (range 8-72 months). Inflammatory CNV was the most common etiology. The mean best corrected visual acuity (BCVA) and mean central macular thickness (CMT) at presentation, were logMAR 0.8 ± 0.3 and 367.6 ± 134.8 µm respectively. At the final visit, CNV in all eyes remained regressed with significant improvement in mean BCVA to logMAR 0.4 ± 0.4 (p < 0.0001) and mean CMT to 242.5 ± 82.4 µm (p < 0.0001). A mean of two intravitreal injections per eye was required for CNV regression.CONCLUSION:
Intravitreal anti-VEGF therapy for pediatric CNV is an effective treatment in majority of affected eyes.Key words
Full text:
1
Database:
MEDLINE
Main subject:
Choroidal Neovascularization
/
Angiogenesis Inhibitors
Type of study:
Diagnostic_studies
/
Etiology_studies
/
Observational_studies
Limits:
Adolescent
/
Child
/
Child, preschool
/
Female
/
Humans
/
Male
Language:
En
Year:
2022
Type:
Article